Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomized, Open, Multi-Center Trial Comparing TNF-Blockade + MTX to MTX+SSZ+HCQ in Patients With Early RA With an Inadequate Response to MTX
Brief Summary: The Swefot trial was designed to compare two treatment strategies for patients with early rheumatoid arthritis (less than 1 year symptom duration): the use of a combination of traditional antirheumatic medications (DMARDs), versus a combination including a newer "biological" anti-TNF medication. In order to make this trial consistent with current practices in rheumatology, all patients were first given the most commonly used antirheumatic medication, methotrexate (MTX). After 3-4 months those patients who had not responded adequately to this treatment were randomized to receive either MTX plus sulfasalazine plus hydroxychloroquine, or MTX plus infliximab. Again, to be truly life-like, the trial allowed patients who could not tolerate one of the added medications to switch in treatment - but keeping with the same strategy - so that sulfasalazine plus hydroxychloroquine could be replaced by cyclosporin A, and infliximab by etanercept. The primary outcome in this trial was the percentage of patients who, after one year of treatment, achieved a "good response" as defined by Eular.


Options:
A: Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Biological: tocilizumab, Drug: methotrexate, Biological: 23-Valent Pneumococcal Polysaccharide Vaccine, Biological: Tetanus Toxoid Adsorbed Vaccine | Arm Label: Tocilizumab + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: tocilizumab, Drug: methotrexate, Biological: 23-Valent Pneumococcal Polysaccharide Vaccine, Biological: Tetanus Toxoid Adsorbed Vaccine | Intervention Type: BIOLOGICAL; Name: tocilizumab; Assigned to Arm(s): Methotrexate, Tocilizumab + Methotrexate | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Methotrexate, Tocilizumab + Methotrexate | Intervention Type: BIOLOGICAL; Name: 23-Valent Pneumococcal Polysaccharide Vaccine; Assigned to Arm(s): Methotrexate, Tocilizumab + Methotrexate | Intervention Type: BIOLOGICAL; Name: Tetanus Toxoid Adsorbed Vaccine; Assigned to Arm(s): Methotrexate, Tocilizumab + Methotrexate
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: conventional DMARD combination | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: MTX plus anti-TNF | Intervention Type: DRUG; Name: conventional DMARD combination; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: MTX plus anti-TNF; Assigned to Arm(s): B
C: Arm Label: TNF-blocking drug; Type: EXPERIMENTAL; Interventions: Drug: Etanercept, Drug: Adalimumab, Drug: Certolizumab Pegol, Drug: Infliximab, Drug: Golimumab | Arm Label: Abatacept; Type: EXPERIMENTAL; Interventions: Drug: Abatacept | Arm Label: Rituximab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Rituximab | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Rituximab | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Certolizumab Pegol; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): TNF-blocking drug
D: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A

Answer: B